{
  "id": 20998525,
  "title": "Aeon Biopharma CEO Robert Bancroft buys $19,590 in company stock",
  "url": "https://urgent.news/2026/11/21/aeon-biopharma-ceo-robert-bancroft-buys-19-590-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-21T05:00:57.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/aeon-biopharma-ceo-robert-bancroft-buys-19590-in-company-stock-93CH-5043166"
  },
  "original_language": "en",
  "account": "Robert E. Bancroft, CEO of AEON Biopharma, Inc., purchased 152,333 shares of the company's Class A Common Stock on November 19, 2026. The transaction, valued at $19,590, occurred as the stock traded near its 52-week low of $0.11. With shares priced between $0.1213 and $0.1345, the weighted average price for the purchase was $0.1286. The move comes after a 20% decline in the stock's value over the past week. The RSI suggests the stock is in oversold territory, potentially influencing the insider's purchase decision. Now directly owning 3,329,436 shares, Mr. Bancroft's stake in the company has increased following this acquisition. The transaction was reported to the Securities and Exchange Commission in a Form 4 filing on November 20, 2026. In related news, AEON Biopharma announced warrant term adjustments, reducing exercise prices for Class A common stock and pre-funded warrants. Laidlaw has initiated coverage with a Buy rating and a price target of $1.80 for the company.",
  "summary": null,
  "key_points": [
    "CEO Robert Bancroft bought 152,333 shares of AEON Biopharma stock on November 19, 2026.",
    "Purchase valued at $19,590 as stock traded near 52-week low of $0.11.",
    "Mr. Bancroft's stake increased to 3,329,436 shares after insider acquisition."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}